Breaking News, Financial News

Financial Report: Ligand

Revenues double in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ligand 1Q Revenues: $11.7 million (+107%) 1Q Earnings: $1.5 million (+32%) Comments: Royalties were up 90% to $5.8 million driven by Promacta and new royalties from Kyprolis. Material sales were $1.5 million, up from $667,000 in 1Q12. Collaborative R&D revenues were $4.3 million, up from $1.9 million 1Q12....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters